Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0779
    -0.0014 (-0.13%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2623
    +0.0001 (+0.01%)
     
  • USD/JPY

    151.2820
    -0.0900 (-0.06%)
     
  • Bitcoin USD

    70,339.22
    +692.16 (+0.99%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,329.69
    +161.62 (+0.40%)
     

Citi's assessment hits Biogen

Shares of the biotech drugmaker soared 74% this spring to an all-time high 242.64 on May 28. But shares fell 7.4% to 206.55 Wed. after Citigroup downgraded its stock to neutral from buy, citing concerns that European officials won't provide regulatory protection for Biogen Idec's (BIIB) Tecfidera, its potential blockbuster multiple sclerosis drug. Citi also said in a report that sales figures to date may be exaggerated, but noted that it likes the drug's prospects and projected '13 U.S. sales of $442 mil.

Advertisement